Phase 2 Trial of Cognitive Treatment NYX-458 Resumes

Phase 2 Trial of Cognitive Treatment NYX-458 Resumes

291489

Phase 2 Trial of Cognitive Treatment NYX-458 Resumes

Aptinyx‘s Phase 2 clinical trial evaluating its investigational oral compound NYX-458 for the treatment of cognitive impairment and mild dementia associated with Parkinson’s disease is resuming patient screening after a temporary pause due to the COVID-19 pandemic. Recruitment is underway at multiple locations in the United States. More information and contacts is available here. “We are pleased to be moving forward in evaluating NYX-458 in patients suffering from cognitive impairment,” Norbert Riedel, PhD, CEO of Aptinyx, said…

You must be logged in to read/download the full post.